1
Cancer genomics guided indication selection
Burning Rock utilizes our own proprietary large-scale genomic dataset based on personalized analyses of Chinese cancer patients*, ntegrates the experience from multi-dimensional clinical/scientific research and published data, to provide a one-stop cancer genomic data solution for biopharma partners, aiming to speed up precision drug development and reduce the risks.
Burning Rock provides effective biomarker clinical trial strategies for biopharma partners, including indication selection, patient screening and stratification, drug efficacy/mechanism exploration and recommendation of clinical study sites.
2
Biomarker discovery for patient stratification
3
Commercial evaluation for targeted detection
4
Site selection based on geographic distribution
＞250,000 testing data*
>20 cancer types
>600 collaborating hospitals
>50 drug clinical studies
>170 publications
>30 biopharma partners